ATRA
Atara Biotherapeutics, Inc. [ATRA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ATRA Stock Summary
Top 10 Correlated Stocks
ATRA
In the News
ATRA Financial details
Company Rating
Sell
Market Cap
84.51M
Income
-276.13M
Revenue
8.57M
Book val./share
-0.92
Cash/share
0.48
Dividend
-
Dividend %
-
Employees
225
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-0.21
Forward P/E
-
PEG
-0.12
P/S
13.06
P/B
-1.22
P/C
1.44
P/FCF
-0.3
Quick Ratio
1.3
Current Ratio
1.5
Debt / Equity
-0.58
LT Debt / Equity
-0.46
-
-
EPS (TTM)
-2.62
EPS next Y
-
EPS next Q
-
EPS this Y
16.52%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
98.88%
EPS Q/Q
-15.15%
-
-
-
-
SMA20
5.97%
SMA50
-17.44%
SMA100
51.06%
Inst Own
61.14%
Inst Trans
0.71%
ROA
-154%
ROE
-783%
ROC
-2.66%
Gross Margin
-26%
Oper. Margin
-6420%
Profit Margin
-6390%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.199-3.08
52W High
-
52W Low
-
RSI
46.61
Rel Volume
0.29
Avg Volume
2.87M
Volume
830.3K
Perf Week
-7.69%
Perf Month
-0.89%
Perf Quarter
-47.6%
Perf Half Y
-55.94%
-
-
-
-
Beta
0.716
-
-
Volatility
0.02%, 0.04%
Prev Close
-3.25%
Price
0.6917
Change
2.35%
ATRA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.22 | 0.62 | 0.08 | |
| Net income per share | -5.67 | -4.15 | -3.63 | -2.24 | -2.61 | |
| Operating cash flow per share | -4.59 | -2.44 | -2.35 | -2.65 | -1.82 | |
| Free cash flow per share | -4.7 | -2.5 | -2.47 | -2.69 | -1.83 | |
| Cash per share | 5.05 | 6.77 | 3.96 | 2.38 | 0.49 | |
| Book value per share | 5.67 | 6.25 | 2.99 | 1.24 | -0.94 | |
| Tangible book value per share | 5.67 | 6.25 | 2.99 | 1.24 | -0.94 | |
| Share holders equity per share | 5.67 | 6.25 | 2.99 | 1.24 | -0.94 | |
| Interest debt per share | 0.31 | 0.2 | 0.3 | 0.72 | 0.6 | |
| Market cap | 845.04M | 1.45B | 1.48B | 334.53M | 54.31M | |
| Enterprise value | 784.86M | 1.26B | 1.4B | 313.29M | 86.2M | |
| P/E ratio | -2.9 | -4.74 | -4.34 | -1.47 | -0.2 | |
| Price to sales ratio | 0 | 0 | 72.58 | 5.26 | 6.34 | |
| POCF ratio | -3.59 | -8.03 | -6.69 | -1.24 | -0.28 | |
| PFCF ratio | -3.5 | -7.84 | -6.39 | -1.22 | -0.28 | |
| P/B Ratio | 2.91 | 3.14 | 5.28 | 2.64 | -0.55 | |
| PTB ratio | 2.91 | 3.14 | 5.28 | 2.64 | -0.55 | |
| EV to sales | 0 | 0 | 68.62 | 4.93 | 10.05 | |
| Enterprise value over EBITDA | -2.65 | -4.09 | -4.1 | -0.95 | -0.33 | |
| EV to operating cash flow | -3.33 | -7 | -6.33 | -1.16 | -0.45 | |
| EV to free cash flow | -3.25 | -6.83 | -6.04 | -1.14 | -0.44 | |
| Earnings yield | -0.34 | -0.21 | -0.23 | -0.68 | -5.08 | |
| Free cash flow yield | -0.29 | -0.13 | -0.16 | -0.82 | -3.58 | |
| Debt to equity | 0.05 | 0.03 | 0.1 | 0.57 | -0.58 | |
| Debt to assets | 0.05 | 0.03 | 0.06 | 0.19 | 0.35 | |
| Net debt to EBITDA | 0.2 | 0.61 | 0.24 | 0.06 | -0.12 | |
| Current ratio | 7.43 | 6.31 | 3.64 | 3.74 | 0.72 | |
| Interest coverage | 0 | 0 | 0 | -141.25 | -50.95 | |
| Income quality | 0.81 | 0.59 | 0.65 | 1.18 | 0.7 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.02 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 3.87 | 1.13 | 5.94 | |
| Research and developement to revenue | 0 | 0 | 13.86 | 4.29 | 25.56 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.02 | 0.05 | 0.02 | 0.01 | |
| Capex to revenue | 0 | 0 | -0.52 | -0.07 | -0.14 | |
| Capex to depreciation | -0.81 | -0.54 | -1.13 | -0.74 | -0.25 | |
| Stock based compensation to revenue | 0 | 0 | 2.65 | 0.85 | 5.29 | |
| Graham number | 26.89 | 24.14 | 15.62 | 7.91 | 7.41 | |
| ROIC | -0.92 | -0.63 | -1.02 | -1.09 | -62.13 | |
| Return on tangible assets | -0.85 | -0.52 | -0.73 | -0.61 | -1.67 | |
| Graham Net | 4.03 | 5.08 | 1.96 | 0.24 | -1.72 | |
| Working capital | 236.25M | 440.37M | 278.84M | 216.16M | -40.36M | |
| Tangible asset value | 290.78M | 462.34M | 279.61M | 126.64M | -99.23M | |
| Net current asset value | 220.83M | 397.49M | 196.11M | 45.3M | -162.87M | |
| Invested capital | 0.05 | 0.03 | 0.1 | 0.57 | -0.58 | |
| Average receivables | 0 | 625K | 1.12M | 20.6M | 37.16M | |
| Average payables | 5.84M | 7.54M | 12.24M | 12.12M | 5.28M | |
| Average inventory | 0 | 0 | 0.5 | 793K | 5.65M | |
| Days sales outstanding | 0 | 0 | 17.69 | 230.93 | 1.45K | |
| Days payables outstanding | 358.61 | 263.31 | 557.06 | 172.15 | 151.32 | |
| Days of inventory on hand | 0 | 0 | 0 | 39.74 | 398.68 | |
| Receivables turnover | 0 | 0 | 20.63 | 1.58 | 0.25 | |
| Payables turnover | 1.02 | 1.39 | 0.66 | 2.12 | 2.41 | |
| Inventory turnover | 0 | 0 | 11.38M | 9.19 | 0.92 | |
| ROE | -1 | -0.66 | -1.22 | -1.8 | 2.78 | |
| Capex per share | -0.11 | -0.06 | -0.11 | -0.04 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.01 | 0.01 | 0.02 | 0.04 | |
| Net income per share | -0.72 | -0.72 | -0.68 | -0.66 | -0.56 | |
| Operating cash flow per share | -0.55 | -0.37 | -0.5 | -0.48 | -0.47 | |
| Free cash flow per share | -0.55 | -0.37 | -0.51 | -0.49 | -0.47 | |
| Cash per share | 2.35 | 1.98 | 1.46 | 0.96 | 0.48 | |
| Book value per share | 1.23 | 0.62 | 0.07 | -0.48 | -0.92 | |
| Tangible book value per share | 1.23 | 0.62 | 0.07 | -0.48 | -0.92 | |
| Share holders equity per share | 1.23 | 0.62 | 0.07 | -0.48 | -0.92 | |
| Interest debt per share | 0.7 | 0.66 | 0.63 | 0.59 | 0.55 | |
| Market cap | 338.42M | 301.51M | 169.2M | 157.47M | 55.45M | |
| Enterprise value | 317.19M | 307.69M | 188.01M | 154.49M | 87.34M | |
| P/E ratio | -1.13 | -1.01 | -0.59 | -0.56 | -0.23 | |
| Price to sales ratio | 1.53K | 245.93 | 176.8 | 73.65 | 13.04 | |
| POCF ratio | -5.95 | -7.85 | -3.2 | -3.07 | -1.1 | |
| PFCF ratio | -5.95 | -7.77 | -3.17 | -3.05 | -1.1 | |
| P/B Ratio | 2.67 | 4.64 | 22.7 | -3.1 | -0.56 | |
| PTB ratio | 2.67 | 4.64 | 22.7 | -3.1 | -0.56 | |
| EV to sales | 1.44K | 250.97 | 196.45 | 72.26 | 20.54 | |
| Enterprise value over EBITDA | -4.2 | -4.1 | -2.74 | -2.3 | -1.68 | |
| EV to operating cash flow | -5.58 | -8.01 | -3.56 | -3.01 | -1.73 | |
| EV to free cash flow | -5.57 | -7.92 | -3.53 | -2.99 | -1.73 | |
| Earnings yield | -0.22 | -0.25 | -0.42 | -0.44 | -1.09 | |
| Free cash flow yield | -0.17 | -0.13 | -0.31 | -0.33 | -0.91 | |
| Debt to equity | 0.57 | 1.04 | 8.68 | -1.22 | -0.58 | |
| Debt to assets | 0.19 | 0.22 | 0.26 | 0.33 | 0.35 | |
| Net debt to EBITDA | 0.28 | -0.08 | -0.27 | 0.04 | -0.61 | |
| Current ratio | 3.74 | 3.3 | 2.31 | 1.5 | 0.72 | |
| Interest coverage | -77.96 | -56.15 | -51.82 | -49.9 | -45.3 | |
| Income quality | 0.76 | 0.51 | 0.74 | 0.74 | 0.83 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 59.93 | 11.31 | 13.93 | 5.73 | 2.69 | |
| Research and developement to revenue | 282.87 | 50.7 | 58.66 | 26.61 | 10.34 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Capex to revenue | -0.17 | -0.33 | -0.52 | -0.13 | -0.01 | |
| Capex to depreciation | -0.03 | -0.33 | -0.42 | -0.23 | -0.04 | |
| Stock based compensation to revenue | 51.42 | 9.6 | 13.12 | 5.21 | 2.33 | |
| Graham number | 4.47 | 3.18 | 1.04 | 2.66 | 3.4 | |
| ROIC | -0.29 | -0.4 | -0.52 | -0.96 | -12.3 | |
| Return on tangible assets | -0.2 | -0.25 | -0.29 | -0.37 | -0.37 | |
| Graham Net | 0.23 | -0.28 | -0.77 | -1.26 | -1.69 | |
| Working capital | 216.16M | 156.31M | 97.77M | 39.61M | -40.36M | |
| Tangible asset value | 126.64M | 64.96M | 7.45M | -50.84M | -99.23M | |
| Net current asset value | 45.3M | -12.94M | -66.67M | -120.93M | -162.87M | |
| Invested capital | 0.57 | 1.04 | 8.68 | -1.22 | -0.58 | |
| Average receivables | 20.24M | 20.31M | 452K | 335K | 17.14M | |
| Average payables | 9.08M | 5.97M | 4.6M | 5.32M | 5.1M | |
| Average inventory | 793K | 3.46M | 6.6M | 7.23M | 8.15M | |
| Days sales outstanding | 16.38K | 29.14 | 47.68 | 6.86 | 721.95 | |
| Days payables outstanding | 152.05 | 2.11K | 128.64 | 224.09 | 104.92 | |
| Days of inventory on hand | 35.1 | 2.23K | 244.38 | 226.84 | 276.44 | |
| Receivables turnover | 0.01 | 3.09 | 1.89 | 13.12 | 0.12 | |
| Payables turnover | 0.59 | 0.04 | 0.7 | 0.4 | 0.86 | |
| Inventory turnover | 2.56 | 0.04 | 0.37 | 0.4 | 0.33 | |
| ROE | -0.59 | -1.15 | -9.54 | 1.37 | 0.61 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ATRA Frequently Asked Questions
What is Atara Biotherapeutics, Inc. stock symbol ?
Atara Biotherapeutics, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol ATRA
What is Atara Biotherapeutics, Inc. stock quote today ?
Atara Biotherapeutics, Inc. stock price is $0.6917 today.
Is Atara Biotherapeutics, Inc. stock public?
Yes, Atara Biotherapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.87M
- Market Capitalization 84.51M
- Employee 225
- CEO Dr. Pascal Touchon D.V.M.
- Headquarters South San Francisco,CA,US
- IPO Date 2014-10-16
-
Website
https://www.atarabio.com 
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
